MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, TNXP had -$23,799K decrease in cash & cash equivalents over the period. -$44,010K in free cash flow.

Cash Flow Overview

Change in Cash
-$23,799K
Free Cash flow
-$44,010K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds, net issuance costs pai...
    • Inventory
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Other non-current assets
    • Accounts receivable, net
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
Net loss
-40,194 -46,910 -77,111
Depreciation and amortization
555 488 1,437
Loss on note
-0 -1,159
Loss on extinguishment of debt
0 0 -2,092
Bad debt expense
-0 31
Issuance costs of derivative instrument
-0 1,837
Inventory write-off
--649 1,318
Amortization of debt discounts
-0 65
Stock-based compensation
1,970 1,789 4,228
Accounts receivable, net
2,548 2,789 -170
Prepaid expenses and other
278 1,002 2,159
Other non-current assets
3,742 --
Inventory
-2,369 -364 -1,362
Accounts payable
1,533 -738 3,732
Operating lease liabilities and rou asset, net
80 -285 -18
Accrued expenses and other current liabilities
-2,063 10,082 1,663
Net cash used in operating activities
-42,318 -39,650 -60,194
Issuance of note
-0 2,012
Proceeds from note
-853 -
Purchase of property and equipment
1,692 1,874 1,495
Net cash used in investing activities
-1,692 -1,021 -3,507
Repurchase of common stock, net of 30 expenses
-7,811 5,949
Repayments of term loan
-0 9,650
Proceeds from espp
79 --
Proceeds, net issuance costs paid of 676 and 2,270, from sale of common stock
20,126 66,954 170,986
Net cash provided by financing activities
20,205 59,143 155,387
Effect of currency rate change on cash
6 -14 -17
Net (decrease) increase in cash, cash equivalents and restricted cash
-23,799 18,458 91,669
Cash, cash equivalents and restricted cash beginning of the period
209,807 191,349 99,680
Cash, cash equivalents and restricted cash end of period
186,008 209,807 191,349
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds, net issuancecosts paid of 676 and...$20,126K Proceeds from espp$79K Net cash provided byfinancing activities$20,205K Effect of currency ratechange on cash$6K Net (decrease)increase in cash, cash...-$23,799K Canceled cashflow$20,211K Inventory-$2,369K Stock-based compensation$1,970K Accounts payable$1,533K Depreciation andamortization$555K Operating leaseliabilities and rou asset,...$80K Net cash used inoperating activities-$42,318K Canceled cashflow$6,507K Net cash used ininvesting activities-$1,692K Net loss-$40,194K Other non-currentassets$3,742K Accounts receivable, net$2,548K Accrued expenses andother current...-$2,063K Prepaid expenses andother$278K Purchase of property andequipment$1,692K

Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals Holding Corp. (TNXP)